本文已被:浏览 498次 下载 424次
Received:March 13, 2022 Published Online:February 20, 2023
Received:March 13, 2022 Published Online:February 20, 2023
中文摘要: 目的 研究替格瑞洛和依折麦布对老年急性ST段抬高型心肌梗死(STEMI)疗效以及预防患者经皮冠状动脉介入治疗(PCI)术后主要心血管不良事件(MACE)发生的价值。方法 选择2016年1月到2021年1月佛山市第一人民医院进行PCI的老年STEMI患者120例,将所有患者随机分为观察组和对照组,各60例。对照组在常规治疗基础上进行替格瑞洛治疗,观察组在对照组基础上加用依折麦布。收集患者的MACE及不良反应,检测白细胞介素(IL)-6、降钙素原(PCT)、超敏C反应蛋白(hs-CRP)水平及左心室舒张末期内径(LVEDD)、左心室射血分数(LVEF)。结果 术前观察组患者的TIMI心肌灌注分级(TMPG)优于对照组(P<0.05),术后两组患者的TMPG比较差异无统计学意义(P>0.05);观察组患者的手术时间短于对照组(P<0.05);观察组患者的MACE发生率低于对照组(11.67% vs28.33%, P<0.05),两组患者的不良反应发生率差异无统计学意义(P>0.05)。经过3个月治疗后,观察组患者的IL-6、PCT、hs-CRP、LVEDD低于对照组,LVEF高于对照组(P<0.05)。结论 替格瑞洛联合依折麦布能够改善PCI术后老年STEMI患者MACE的发生率、炎症反应及心功能,具有较好的临床应用价值。
Abstract:ObjectiveTo study the efficacy of Ticagrelor and ezetimibe in the treatment of elderly patients with acute ST-elevation myocardial infarction (STEMI) and the value of preventing major adverse cardiovascular events (MACE) after the patients undergoing percutaneous coronary intervention (PCI). MethodsA total of 120 elderly STEMI patients receiving PCI in the First Peoples Hospital of Foshan from January 2016 to January 2021 were selected and were randomly divided into observation group and control group (n=60, each). Based on the conventional treatment in both groups, ticagrelor was used in control group, and ezetimibe with ticagrelor was given in observation group. MACE and adverse reactions were collected after PCI, levels of Interleukin(IL)-6, procalcitonin (PCT) and high-sensitivity C-reactive protein (hs-CRP) were detected, and left ventricular end diastolic diameter (LVEDD) and left ventricular ejection fraction (LVEF) were measured. ResultsBefore operation, TIMI myocardial perfusion grade(TMPG) of patients in observation group was better than that in control group (P<0.05), and there was no significant difference in it after operation between two groups (P>0.05).Compared with those in control group, the operation time and the incidence of MACE (11.67% vs28.33%) significantly decreased in observation group (P<0.05). The incidence of adverse reactions was similar in the two groups (P>0.05). After 3 months of treatment, IL-6, PCT and hs-CRP levels and LVEDD decreased, and LVEF increased in observation group compared with those in control group (P<0.05). ConclusionTicagrelor combined with ezetimibe can reduce the incidence of MACE and the inflammatory response, improve the cardiac function and have a good clinical application value in elderly STEMI patients after PCI.
keywords: Ticagrelor Ezetimibe Acute myocardial infarction Percutaneous coronary intervention Cardiac function Adverse cardiac event
文章编号: 中图分类号: 文献标志码:B
基金项目:广东省医学科研基金项目(A2017494);佛山市卫生健康局医学科研课题项目(20220361);佛山科技局医学类科技攻关自筹经费类科技创新项目(2220001005274)
Author Name | Affiliation |
YANG Zhen-sheng, YOU Wei, CAI Wei-biao | The First People's Hospital of Foshan, Foshan, Guangdong 528000, China |
Author Name | Affiliation |
YANG Zhen-sheng, YOU Wei, CAI Wei-biao | The First People's Hospital of Foshan, Foshan, Guangdong 528000, China |
引用文本: